TGF-β–mediated signaling is considered a key event in the pathogenesis of IPF and its inhibition via a highly selective, ATP-competitive ALK5 inhibitor — SB525334 — attenuates pulmonary fibrosis in vivo (60, 61). This evidence concerns the gene TGFBR1 and idiopathic pulmonary fibrosis.